<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03784781</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180357</org_study_id>
    <nct_id>NCT03784781</nct_id>
  </id_info>
  <brief_title>Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma</brief_title>
  <acronym>CLASSE</acronym>
  <official_title>Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are to show that the number of type 2 innate lymphoid cells&#xD;
      (ILC2) of the bronchial mucosa and in bronchoalveolar lavages (BAL) are higher in asthmatic&#xD;
      children than in non-asthmatics, that the number of ILC2 of the bronchial mucosa and in BAL&#xD;
      correlate with the number of bronchial and BAL eosinophils, and to determine whether there is&#xD;
      a correlation between plasma and bronchial and BAL ILC2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe asthma of the child is characterized by chronic eosinophilic infiltration of the&#xD;
      bronchial mucosa associated with bronchial remodeling.&#xD;
&#xD;
      The mechanisms responsible for these phenomena are still misunderstood. Animal models suggest&#xD;
      that type 2 innate lymphoid cells (ILC2) may be responsible for inflammation and bronchial&#xD;
      remodeling in asthma. In mice, ILC2 stimulated by the pulmonary epithelium by viral&#xD;
      aggression or allergenic exposure release cytokines of the TH2 type such as IL-5 and IL-13&#xD;
      and amphiregulin, involved in the recruitment and differentiation of eosinophils,&#xD;
      bronchoconstriction, mucus secretion and the restoration of epithelial integrity.&#xD;
&#xD;
      In humans, ILC2 would be more abundant in the bronchoalveolar lavage (BAL) and peripheral&#xD;
      blood of asthmatic patients compared to control subjects. However, the presence of ILC2 in&#xD;
      the bronchial mucosa of asthmatic patients has never been identified.&#xD;
&#xD;
      The hypothesis tested is that ILC2 are more abundant in bronchial mucosa, BAL, and blood in&#xD;
      children with severe asthma than in non-asthmatics. The results of this study would improve&#xD;
      the knowledge of the mechanisms responsible for bronchial inflammation in asthma, consider&#xD;
      therapies to prevent its development and modify the natural history of the disease.&#xD;
&#xD;
      The main objectives of this study are to show that the number of ILC2 in bronchial mucosa and&#xD;
      BAL is higher in asthmatic children than in non-asthmatics, that the number of ILC2 in the&#xD;
      bronchial mucosa and BAL is correlated with the number of eosinophils in bronchial mucosa and&#xD;
      BAL, to determine whether the number of ILC2 in lungs correlate with asthma symptoms, and to&#xD;
      determine whether there is a correlation between plasma and bronchial ILC2.&#xD;
&#xD;
      Bronchoscopy with BAL and bronchial mucosal biopsies will be performed in 20 children with&#xD;
      severe asthma and 20 control subjects in the department of pediatric pulmonology and allergy&#xD;
      of Necker Hospital.&#xD;
&#xD;
      ILC2 will be identified in the BAL, in the bronchial mucosa and peripheral blood by flow&#xD;
      cytometry. The median values of the number of ILC2 will be compared between asthmatic and&#xD;
      non-asthmatic patients by the Mann-Whitney non-parametric test. The correlations will be&#xD;
      established by the Spearman rank test. A value of p &lt; 0.05 will be considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study never started&#xD;
  </why_stopped>
  <start_date type="Actual">June 9, 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of type 2 innate lymphoid cells</measure>
    <time_frame>Day 0</time_frame>
    <description>Type 2 innate lymphoid cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Eosinophils</measure>
    <time_frame>Day 0</time_frame>
    <description>Eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway remodeling: reticular basement membrane thickness</measure>
    <time_frame>Day 0</time_frame>
    <description>Reticular basement membrane thickness will be expressed in µm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway remodeling: airway smooth muscle area</measure>
    <time_frame>Day 0</time_frame>
    <description>The percentage of the submucosa occupied by airway smooth muscle will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The bundles of airway smooth muscle will be enclosed by a line and the area they occupied will be calculated by image analysis. The airway smooth muscle area will be expressed as the percentage of surface of the submucosa occupied by airway smooth muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway remodeling: epithelial integrity</measure>
    <time_frame>Day 0</time_frame>
    <description>Epithelial integrity will be defined as the percentage of the total length of epithelium that will be intact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway remodeling: vessel number</measure>
    <time_frame>Day 0</time_frame>
    <description>The number of vessels stained with anti-CD31 mAb will be determined from at least one grid (0.1 mm2) per biopsy, and reported as the median number of positive sections per 0.1 mm2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway remodeling: mucus gland area</measure>
    <time_frame>Day 0</time_frame>
    <description>The percentage of the submucosa occupied by mucus gland will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The mucus glands will be enclosed by a line and the area occupied will be calculated by image analysis. The mucus gland area will be expressed as the percentage of surface of the submucosa occupied by mucus gland.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway inflammation: bronchoalveolar lavage (BAL)</measure>
    <time_frame>Day 0</time_frame>
    <description>BAL fluid will be assed for inflammation&#xD;
The number of eosinophils will be assessed and expressed percentage of total cells in BAL&#xD;
The number of neutrophils will be assessed and expressed percentage of total cells in BAL&#xD;
The number of macrophages will be assessed and expressed percentage of total cells in BAL&#xD;
The number of basophils will be assessed and expressed percentage of total cells in BAL&#xD;
The number of mast cells will be assessed and expressed percentage of total cells in BAL&#xD;
The number of innate lymphoid cells will be assessed and expressed percentage of total cells in BAL&#xD;
The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells in BAL&#xD;
The number of invariant natural killer T cells will be assessed and expressed percentage of total cells in BAL&#xD;
The number of gammadelta T cells will be assessed and expressed percentage of total cells in BAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway inflammation: bronchial mucosa</measure>
    <time_frame>Day 0</time_frame>
    <description>Bronchial sections will be stained with May-Grunwald-Giemsa.The number of inflammatory cells will be assessed in the submucosa and expressed as the number of cells per square millimeters of submucosal area.&#xD;
The number of eosinophils will be assessed and expressed per square millimeters of submucosal area&#xD;
The number of neutrophils in the submucosa will be assessed and expressed per square millimeters of submucosal area&#xD;
The number of mast cells (c-kit positive cells) in the submucosa will be assessed and expressed per square millimeters of submucosal area&#xD;
The number of IgE stained with anti-IgE Ab in the submucosa and the epithelium will be assessed and expressed per square millimeters of submucosal area&#xD;
The expression of cytokines in the mucosa will be assessed by multiplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation in blood</measure>
    <time_frame>Day 0</time_frame>
    <description>The number of eosinophils will be assessed and expressed percentage of total cells in blood&#xD;
The number of neutrophils will be assessed and expressed percentage of total cells in blood&#xD;
The number of basophils will be assessed and expressed percentage of total cells in blood&#xD;
The number of lymphocytes will be assessed and expressed percentage of total cells in blood&#xD;
The number of innate lymphoid cells will be assessed and expressed percentage of total cells in blood&#xD;
The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells and T cells in blood&#xD;
The number of invariant natural killer T cells will be assessed and expressed percentage of total cells and T cells in blood&#xD;
The number of gammadelta T cells will be assessed and expressed percentage of total cells and T cells in blood&#xD;
The expression of cytokine will be assessed using multiplex analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic signature</measure>
    <time_frame>Day 0</time_frame>
    <description>Non-targeted metabolomics analysis will be performed on plasma. Metabolic profiles will be obtained using two complementary LC-MS methods, to identify metabolites discriminating different patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota analysis</measure>
    <time_frame>Day 0</time_frame>
    <description>Microbiota analysis will be performed on BAL using PCR ARN 16S.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>Asthmatic children</arm_group_label>
    <description>Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe</description>
    <arm_group_label>Asthmatic children</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection (+15mL/ current care)</description>
    <arm_group_label>Asthmatic children</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bronchoalveolar lavage</intervention_name>
    <description>Bronchoalveolar lavage fluid (3mL/Kg)</description>
    <arm_group_label>Asthmatic children</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Minors hospitalized in the department of pediatric pulmonology and allergy of Necker&#xD;
        Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Controls :&#xD;
&#xD;
          -  Minors aged 6 to 18 matched in age with severe asthmatic children&#xD;
&#xD;
          -  Non-asthmatic children hospitalized in the department of pediatric pulmonology and&#xD;
             allergy in Necker Hospital&#xD;
&#xD;
          -  To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood&#xD;
             collection&#xD;
&#xD;
        Severe asthmatic children :&#xD;
&#xD;
          -  Minors aged 6 to 18&#xD;
&#xD;
          -  Children hospitalized in the department of pediatric pulmonology and allergy in Necker&#xD;
             Hospital&#xD;
&#xD;
          -  To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood&#xD;
             collection&#xD;
&#xD;
          -  Severe uncontrolled asthma is defined by the need to maintain a treatment with high&#xD;
             doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an&#xD;
             anti-leukotriene&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with an immune deficiency, will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Lezmi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe asthma in children</keyword>
  <keyword>Type 2 innate lymphoid cells (ILC2)</keyword>
  <keyword>bronchial mucosa</keyword>
  <keyword>bronchoalveolar lavages</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimercaprol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03784781
org study id: APHP180357
nct id: NCT03784781
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The main objectives of this study are to show that the number of type 2 innate lymphoid cells
      (ILC2) of the bronchial mucosa and in bronchoalveolar lavages (BAL) are higher in asthmatic
      children than in non-asthmatics, that the number of ILC2 of the bronchial mucosa and in BAL
      correlate with the number of bronchial and BAL eosinophils, and to determine whether there is
      a correlation between plasma and bronchial and BAL ILC2.
Severe asthma of the child is characterized by chronic eosinophilic infiltration of the
      bronchial mucosa associated with bronchial remodeling.

      The mechanisms responsible for these phenomena are still misunderstood. Animal models suggest
      that type 2 innate lymphoid cells (ILC2) may be responsible for inflammation and bronchial
      remodeling in asthma. In mice, ILC2 stimulated by the pulmonary epithelium by viral
      aggression or allergenic exposure release cytokines of the TH2 type such as IL-5 and IL-13
      and amphiregulin, involved in the recruitment and differentiation of eosinophils,
      bronchoconstriction, mucus secretion and the restoration of epithelial integrity.

      In humans, ILC2 would be more abundant in the bronchoalveolar lavage (BAL) and peripheral
      blood of asthmatic patients compared to control subjects. However, the presence of ILC2 in
      the bronchial mucosa of asthmatic patients has never been identified.

      The hypothesis tested is that ILC2 are more abundant in bronchial mucosa, BAL, and blood in
      children with severe asthma than in non-asthmatics. The results of this study would improve
      the knowledge of the mechanisms responsible for bronchial inflammation in asthma, consider
      therapies to prevent its development and modify the natural history of the disease.

      The main objectives of this study are to show that the number of ILC2 in bronchial mucosa and
      BAL is higher in asthmatic children than in non-asthmatics, that the number of ILC2 in the
      bronchial mucosa and BAL is correlated with the number of eosinophils in bronchial mucosa and
      BAL, to determine whether the number of ILC2 in lungs correlate with asthma symptoms, and to
      determine whether there is a correlation between plasma and bronchial ILC2.

      Bronchoscopy with BAL and bronchial mucosal biopsies will be performed in 20 children with
      severe asthma and 20 control subjects in the department of pediatric pulmonology and allergy
      of Necker Hospital.

      ILC2 will be identified in the BAL, in the bronchial mucosa and peripheral blood by flow
      cytometry. The median values of the number of ILC2 will be compared between asthmatic and
      non-asthmatic patients by the Mann-Whitney non-parametric test. The correlations will be
      established by the Spearman rank test. A value of p < 0.05 will be considered significant.
observational model: Case-Control
time perspective: Cross-Sectional
measure: Number of type 2 innate lymphoid cells
time frame: Day 0
description: Type 2 innate lymphoid cells
measure: Number of Eosinophils
time frame: Day 0
description: Eosinophils
measure: Airway remodeling: reticular basement membrane thickness
time frame: Day 0
description: Reticular basement membrane thickness will be expressed in µm.
measure: Airway remodeling: airway smooth muscle area
time frame: Day 0
description: The percentage of the submucosa occupied by airway smooth muscle will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The bundles of airway smooth muscle will be enclosed by a line and the area they occupied will be calculated by image analysis. The airway smooth muscle area will be expressed as the percentage of surface of the submucosa occupied by airway smooth muscle.
measure: Airway remodeling: epithelial integrity
time frame: Day 0
description: Epithelial integrity will be defined as the percentage of the total length of epithelium that will be intact.
measure: Airway remodeling: vessel number
time frame: Day 0
description: The number of vessels stained with anti-CD31 mAb will be determined from at least one grid (0.1 mm2) per biopsy, and reported as the median number of positive sections per 0.1 mm2.
measure: Airway remodeling: mucus gland area
time frame: Day 0
description: The percentage of the submucosa occupied by mucus gland will be determined on hematoxylin-eosin-stained and anti-airway smooth muscle antibody treated sections, respectively. The mucus glands will be enclosed by a line and the area occupied will be calculated by image analysis. The mucus gland area will be expressed as the percentage of surface of the submucosa occupied by mucus gland.
measure: Airway inflammation: bronchoalveolar lavage (BAL)
time frame: Day 0
description: BAL fluid will be assed for inflammation
The number of eosinophils will be assessed and expressed percentage of total cells in BAL
The number of neutrophils will be assessed and expressed percentage of total cells in BAL
The number of macrophages will be assessed and expressed percentage of total cells in BAL
The number of basophils will be assessed and expressed percentage of total cells in BAL
The number of mast cells will be assessed and expressed percentage of total cells in BAL
The number of innate lymphoid cells will be assessed and expressed percentage of total cells in BAL
The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells in BAL
The number of invariant natural killer T cells will be assessed and expressed percentage of total cells in BAL
The number of gammadelta T cells will be assessed and expressed percentage of total cells in BAL
measure: Airway inflammation: bronchial mucosa
time frame: Day 0
description: Bronchial sections will be stained with May-Grunwald-Giemsa.The number of inflammatory cells will be assessed in the submucosa and expressed as the number of cells per square millimeters of submucosal area.
The number of eosinophils will be assessed and expressed per square millimeters of submucosal area
The number of neutrophils in the submucosa will be assessed and expressed per square millimeters of submucosal area
The number of mast cells (c-kit positive cells) in the submucosa will be assessed and expressed per square millimeters of submucosal area
The number of IgE stained with anti-IgE Ab in the submucosa and the epithelium will be assessed and expressed per square millimeters of submucosal area
The expression of cytokines in the mucosa will be assessed by multiplex
measure: Inflammation in blood
time frame: Day 0
description: The number of eosinophils will be assessed and expressed percentage of total cells in blood
The number of neutrophils will be assessed and expressed percentage of total cells in blood
The number of basophils will be assessed and expressed percentage of total cells in blood
The number of lymphocytes will be assessed and expressed percentage of total cells in blood
The number of innate lymphoid cells will be assessed and expressed percentage of total cells in blood
The number of mucosal associated invariant T (MAIT) cells will be assessed and expressed percentage of total cells and T cells in blood
The number of invariant natural killer T cells will be assessed and expressed percentage of total cells and T cells in blood
The number of gammadelta T cells will be assessed and expressed percentage of total cells and T cells in blood
The expression of cytokine will be assessed using multiplex analysis
measure: Metabolomic signature
time frame: Day 0
description: Non-targeted metabolomics analysis will be performed on plasma. Metabolic profiles will be obtained using two complementary LC-MS methods, to identify metabolites discriminating different patients.
measure: Microbiota analysis
time frame: Day 0
description: Microbiota analysis will be performed on BAL using PCR ARN 16S.
arm group label: Asthmatic children
description: Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
arm group label: Controls
description: Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
intervention type: Biological
intervention name: Biopsy
description: Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
arm group label: Asthmatic children
arm group label: Controls
intervention type: Biological
intervention name: Blood collection
description: Blood collection (+15mL/ current care)
arm group label: Asthmatic children
arm group label: Controls
intervention type: Biological
intervention name: Bronchoalveolar lavage
description: Bronchoalveolar lavage fluid (3mL/Kg)
arm group label: Asthmatic children
arm group label: Controls
Serum and tissue
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 6 Years
maximum age: 18 Years
healthy volunteers: No
last name: Guillaume Lezmi, MD, PhD
role: Principal Investigator
affiliation: Assistance Publique - Hôpitaux de Paris
facility: 
country: France
responsible party type: Sponsor
mesh term: Asthma
mesh term: Dimercaprol
sharing ipd: No